Robert Ilaria
Impact in
- Hematology top 0.5%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
- Hematology 17
- Chronic Myeloid Leukemia Treatments 14
- Oncology 31
- Vascular Tumors and Angiosarcomas 7
- Cancer Treatment and Pharmacology 7
- Cytokine Signaling Pathways and Interactions 5
- Co-authors
- Richard A. Van EttenNicholas C. WolffGeorge Q. DaleyRyan P. MillionShaoguang LiJames A. RichardsonSusan EliazerEric N. Olson
- Journals
- Blood (6 papers)Journal of Clinical Oncology (5 papers)Annals of Oncology (4 papers)Cancer Chemotherapy and Pharmacology (4 papers)Clinical Cancer Research (2 papers)
- Partner nations
- United StatesUnited KingdomSpain
In The Last Decade
Robert Ilaria
56 papers receiving 3.1k citations
Hit Papers
Peers
Comparison fields: 5 of 100
- Hematology 1.3k
- Genetics 833
- Oncology 1.1k
- Rheumatology 427
- Immunology 428
Countries citing papers authored by Robert Ilaria
This map shows the geographic impact of Robert Ilaria's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Ilaria with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Ilaria more than expected).
Fields of papers citing papers by Robert Ilaria
This network shows the impact of papers produced by Robert Ilaria. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Ilaria. The network helps show where Robert Ilaria may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Robert Ilaria, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2023 | 48 | |
| 3 | 2018 | 9 | |
| 4 | 2018 | 10 | |
| 5 | 2017 | 75 | |
| 6 | 2016 | 1 | |
| 7 | Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial Hit paper breakdown → | 2016 | 436 |
| 8 | 2016 | 1 | |
| 9 | 2012 | 14 | |
| 10 | 2011 | 31 | |
| 11 | 2005 | 31 | |
| 12 | 2003 | 18 | |
| 13 | 2002 | 56 | |
| 14 | 2000 | 37 | |
| 15 | 1999 | 130 | |
| 16 | 1999 | 382 | |
| 17 | 1998 | 213 | |
| 18 | 1996 | 407 | |
| 19 | 1995 | 15 | |
| 20 | Diagnostic advances in impotence. | 1978 | 2 |
About Robert Ilaria
Robert Ilaria is a scholar working on Hematology, Oncology, Biophysics, Genetics and Pulmonary and Respiratory Medicine, having authored 57 papers that have together received 3.1k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (14 papers), Sarcoma Diagnosis and Treatment (13 papers), Vascular Tumors and Angiosarcomas (7 papers), Eosinophilic Disorders and Syndromes (7 papers), Cancer Treatment and Pharmacology (7 papers), Lymphoma Diagnosis and Treatment (5 papers), Cytokine Signaling Pathways and Interactions (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). The work is most often cited by research in Hematology (1.3k citations), Genetics (833 citations), Oncology (1.1k citations), Rheumatology (427 citations) and Immunology (428 citations). Robert Ilaria has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Richard A. Van Etten, Nicholas C. Wolff, George Q. Daley, Ryan P. Million, Shaoguang Li, James A. Richardson, Susan Eliazer, Eric N. Olson, Jeffrey A. Spencer and Robert G. Hawley. Their work appears in journals such as Blood, Journal of Clinical Oncology, Annals of Oncology, Cancer Chemotherapy and Pharmacology and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.